Similar companies
Income Statement (USD)
| Q4 '24 | QoQ | |
|---|---|---|
| Operating expense | 34M | 2.2% |
| Net Income | -33M | 6.4% |
| EBITDA | -23M | 28.6% |
Balance Sheet (USD)
| Q4 '24 | QoQ | |
|---|---|---|
| Total Assets | 185M | 9.5% |
| Total Liabilities | 33M | 8.4% |
| Total Equity | 152M | 12.6% |
| Shares Outstanding | 50M | 1.3% |
Cash Flow (USD)
| Q4 '24 | QoQ | |
|---|---|---|
| Cash from operations | -23M | 13.8% |
| Cash from financing | 4.4M | 6057.7% |
EPS
Financial Highlights for Cabaletta Bio in Q4 '24
Operating Expenses for this period were 34M, showing a 2.2% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -33M, showing a -6.4% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -23M, showing a 28.6% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Cabaletta Bio faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
